Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2017-11-16
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the
efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the
progression of IPF in these participants.
Phase:
Phase 2
Details
Lead Sponsor:
FibroGen
Treatments:
Antibodies Antibodies, Monoclonal Immunoglobulin G Immunoglobulins Nintedanib Pirfenidone